Bringing automated next-generation sequencing to every oncology clinic

Kathy Davy, President of Clinical Next Generation Sequencing at Thermo Fisher Scientific, shares how the Genexus DX system is transforming precision oncology in the United States. By fully automating the next-generation sequencing (NGS) workflow, from nucleic acid extraction to results, Genexus DX and the Oncomine DX Express test empower even small and community hospitals to deliver rapid, high-quality genomic insights in-house. This breakthrough closes critical access gaps, enabling faster, more informed treatment decisions for cancer patients. With FDA approval as a companion diagnostic for targeted lung cancer therapy and broad tumor profiling capabilities, this solution brings advanced testing directly to where patients are treated. Looking ahead, the integration of AI promises to further accelerate data analysis and help clinicians match patients to the best therapies with unprecedented speed and accuracy.

This interview was recorded for CLINICAL24 2025